Clinical Trial Update: An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension [Phase 2]

View source ↗

Summary

A Phase 2 8-week trial evaluated the dose response of AHU377 in combination with valsartan in patients with mild-to-moderate systolic hypertension; the study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• AHU377
• VALSARTAN (Valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Systolic Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2015-08-18